Ultragenyx Pharmaceutical Inc. RARE

NAS: RARE | ISIN: US90400D1081 17/05/2024

41,87 USD (-1,74%)

(-1,74%) 17/05/2024

Grafiek Ultragenyx Pharmaceutical Inc.

Grafiek Ultragenyx Pharmaceutical Inc.

1 dag1d -1,74%
1 week1w 2,22%
1 maand1m -4,17%
3 maanden3m -12,53%
6 maanden6m 6,40%
1 jaar1j -17,43%
5 jaar5j -28,48%

Ultragenyx Pharmaceutical Inc. in het nieuws

Toon enkel gratis nieuws

4 januari 2024 · Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) · Persbericht

18 december 2023 · Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) · Persbericht

3 maart 2021 · Ultragenyx to Present at Barclays Global Healthcare Conference · Persbericht

17 februari 2021 · Ultragenyx to Present at Upcoming Investor Conferences · Persbericht

11 februari 2021 · Ultragenyx Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Update · Persbericht

4 februari 2021 · Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2020 Financial Results and Corporate Update · Persbericht

21 januari 2021 · Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX701, a New Gene Therapy for the Treatment of Wilson Disease · Persbericht

8 januari 2021 · Ultragenyx Announces Progress Across Broad Gene Therapy Portfolio and Positive Longer-Term Data from Multiple Phase 1/2 Gene Therapy Studies · Persbericht

5 januari 2021 · Ultragenyx to Present at 39th Annual J.P. Morgan Virtual Healthcare Conference · Persbericht

Profiel Ultragenyx Pharmaceutical Inc.

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: www.ultragenyx.com

Hoofdzetel: Novato, California Verenigde Staten

CEO: Emil Kakkis

Werknemers: 1.563

Aandelen Ultragenyx Pharmaceutical Inc.

Beurswaarde: 3,48 miljard USD

Effecten: 83,13 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 1,16

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe